Pacira Pharmaceuticals (PCRX) Posts Q1 Loss of 19c/Share

Pacira Pharmaceuticals (NASDAQ: PCRX) reported Q1 EPS of ($0.19), $0.13 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $36.7 million versus the consensus estimate of $35.4 million.

For earnings history and earnings-related data on Pacira Pharmaceuticals (PCRX) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• EquipmentShare.com Inc. (EQPT) Reports Q2 EPS of $0.18; Offers Guidance
• Southland Holdings (SLND) Misses Q2 EPS by 122c